Ken Griffin Alkermes Plc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$23.01 - $28.55 $23,010 - $28,550	-1,000 Reduced 6.49%	14,400 $403,000
Q2 2024 Aug 14, 2024	SELL	$23.21 - $27.24 $7.26 Million - $8.52 Million	-312,600 Reduced 95.3%	15,400 $371,000
Q1 2024 May 15, 2024	BUY	$26.4 - $32.56 $7.46 Million - $9.19 Million	282,400 Added 619.3%	328,000 $8.88 Million
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $102,828 - $126,192	-4,400 Reduced 8.8%	45,600 $1.26 Million
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $679,250 - $799,250	25,000 Added 100.0%	50,000 $1.4 Million
Q2 2023 Aug 14, 2023	SELL	$28.34 - $33.63 $93,522 - $110,979	-3,300 Reduced 11.66%	25,000 $782,000
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $64.6 Million - $74 Million	-2,550,500 Reduced 98.9%	28,300 $797,000
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $44.8 Million - $53.6 Million	2,043,900 Added 382.11%	2,578,800 $67.4 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $11.1 Million - $16 Million	503,500 Added 1603.5%	534,900 $11.9 Million

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.88B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.